JP2012512886A5 - - Google Patents

Download PDF

Info

Publication number
JP2012512886A5
JP2012512886A5 JP2011542419A JP2011542419A JP2012512886A5 JP 2012512886 A5 JP2012512886 A5 JP 2012512886A5 JP 2011542419 A JP2011542419 A JP 2011542419A JP 2011542419 A JP2011542419 A JP 2011542419A JP 2012512886 A5 JP2012512886 A5 JP 2012512886A5
Authority
JP
Japan
Prior art keywords
substituted
alkyl
hydrogen
membered
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011542419A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012512886A (ja
JP5557849B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/068394 external-priority patent/WO2010080474A1/en
Publication of JP2012512886A publication Critical patent/JP2012512886A/ja
Publication of JP2012512886A5 publication Critical patent/JP2012512886A5/ja
Application granted granted Critical
Publication of JP5557849B2 publication Critical patent/JP5557849B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011542419A 2008-12-19 2009-12-17 カルバゾールおよびカルボリンキナーゼ阻害剤 Expired - Fee Related JP5557849B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13904208P 2008-12-19 2008-12-19
US61/139,042 2008-12-19
PCT/US2009/068394 WO2010080474A1 (en) 2008-12-19 2009-12-17 Carbazole and carboline kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2012512886A JP2012512886A (ja) 2012-06-07
JP2012512886A5 true JP2012512886A5 (enExample) 2013-01-24
JP5557849B2 JP5557849B2 (ja) 2014-07-23

Family

ID=41625988

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011542419A Expired - Fee Related JP5557849B2 (ja) 2008-12-19 2009-12-17 カルバゾールおよびカルボリンキナーゼ阻害剤

Country Status (6)

Country Link
US (1) US8815840B2 (enExample)
EP (1) EP2370407B1 (enExample)
JP (1) JP5557849B2 (enExample)
CN (1) CN102325752B (enExample)
ES (1) ES2490867T3 (enExample)
WO (1) WO2010080474A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8084620B2 (en) 2008-12-19 2011-12-27 Bristol-Myers Squibb Company Carbazole carboxamide compounds useful as kinase inhibitors
AU2010289497B2 (en) 2009-09-03 2016-04-14 Bristol-Myers Squibb Company JAK2 inhibitors and their use for the treatment of myeloproliferative diseases and cancer
EP2961747B1 (en) 2013-02-27 2017-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
US9492460B2 (en) * 2013-02-27 2016-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
CN105492444B (zh) * 2013-07-02 2018-09-07 百时美施贵宝公司 作为rock抑制剂的三环吡啶-甲酰胺衍生物
EP3016950B1 (en) * 2013-07-02 2017-06-07 Bristol-Myers Squibb Company Tricyclic pyrido-carboxamide derivatives as rock inhibitors
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
EA201990240A1 (ru) * 2013-12-24 2019-06-28 Бристол-Маерс Сквибб Компани Новые трициклические соединения в качестве противораковых средств
US9458156B2 (en) 2014-12-23 2016-10-04 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
EA036518B1 (ru) * 2015-02-02 2020-11-18 Юсб Байофарма Спрл Производные 9h-пирролодипиридина
GB201512678D0 (en) * 2015-07-20 2015-08-26 Wista Lab Ltd Methods of chemical synthesis
MA52119A (fr) 2015-10-19 2018-08-29 Ncyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
PT3377488T (pt) 2015-11-19 2022-11-21 Incyte Corp Compostos heterocíclicos como imunomoduladores
SI3394033T1 (sl) 2015-12-22 2021-03-31 Incyte Corporation Heterociklične spojine kot imunomodulatorji
WO2017192961A1 (en) 2016-05-06 2017-11-09 Incyte Corporation Heterocyclic compounds as immunomodulators
EP3464279B1 (en) 2016-05-26 2021-11-24 Incyte Corporation Heterocyclic compounds as immunomodulators
PL3472167T3 (pl) 2016-06-20 2022-12-19 Incyte Corporation Związki heterocykliczne jako immunomodulatory
KR102625861B1 (ko) * 2016-06-28 2024-01-17 삼성디스플레이 주식회사 헤테로시클릭 화합물 및 이를 포함한 유기 발광 소자
EP3484866B1 (en) 2016-07-14 2022-09-07 Incyte Corporation Heterocyclic compounds as immunomodulators
ES2941716T3 (es) 2016-08-29 2023-05-25 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
US20180179201A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Heterocyclic compounds as immunomodulators
KR102696516B1 (ko) 2016-12-22 2024-08-22 인사이트 코포레이션 면역조절제로서의 벤조옥사졸 유도체
EP3558973B1 (en) 2016-12-22 2021-09-15 Incyte Corporation Pyridine derivatives as immunomodulators
WO2018119286A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Bicyclic heteroaromatic compounds as immunomodulators
EP4212529B1 (en) 2018-03-30 2025-01-29 Incyte Corporation Heterocyclic compounds as immunomodulators
FI4219492T3 (fi) 2018-05-11 2025-02-17 Incyte Corp Heterosyklisiä yhdisteitä immunomodulaattoreina
GB201809102D0 (en) * 2018-06-04 2018-07-18 Univ Oxford Innovation Ltd Compounds
US10947253B2 (en) 2019-08-05 2021-03-16 Ankh Life Sciences Limited Fused polycyclic dimers
CA3150434A1 (en) 2019-08-09 2021-02-18 Incyte Corporation Salts of a pd-1/pd-l1 inhibitor
US20220372135A1 (en) 2019-09-27 2022-11-24 Disc Medicine, Inc. Methods for treating myelofibrosis and related conditions
AR120109A1 (es) 2019-09-30 2022-02-02 Incyte Corp Compuestos de pirido[3,2-d]pirimidina como inmunomoduladores
JP7545467B2 (ja) * 2019-10-04 2024-09-04 ブリストル-マイヤーズ スクイブ カンパニー 置換カルバゾール化合物
IL292524A (en) 2019-11-11 2022-06-01 Incyte Corp Salts and crystalline forms of a pd-1/pd-l1 inhibitor
US12129265B2 (en) 2020-07-21 2024-10-29 Ankh Life Sciences Limited Therapeutic agents and uses thereof
WO2022099075A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Crystalline form of a pd-1/pd-l1 inhibitor
PE20231438A1 (es) 2020-11-06 2023-09-14 Incyte Corp Proceso para hacer un inhibidor de pd-1/pd-l1 y sales y formas cristalinas del mismo
US11780836B2 (en) 2020-11-06 2023-10-10 Incyte Corporation Process of preparing a PD-1/PD-L1 inhibitor
CN113880836B (zh) * 2021-10-18 2023-03-14 浙江中医药大学 1,5,8-三取代γ-咔啉类衍生物及其制备方法和应用
EP4434968A4 (en) * 2021-11-19 2025-10-22 Nain Biotech Hangzhou Co Ltd TETRAHYDROCARBAZOLE COMPOUND, PHARMACEUTICAL COMPOSITION AND USE THEREOF

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532261A (en) * 1994-12-12 1996-07-02 Merck & Co., Inc. Carbapenem antibiotics, compositions containing such compounds and methods of use
US20050165029A1 (en) * 2004-01-13 2005-07-28 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
TW200626142A (en) 2004-09-21 2006-08-01 Glaxo Group Ltd Chemical compounds
MX2007016541A (es) * 2005-06-30 2008-03-07 Smithkline Beecham Corp Compuestos quimicos.
AU2006316322B2 (en) * 2005-11-22 2011-08-25 Merck Canada Inc. Tricyclic compounds useful as inhibitors of kinases
EP1959737A4 (en) * 2005-12-16 2010-12-08 Glaxosmithkline Llc CHEMICAL COMPOUNDS

Similar Documents

Publication Publication Date Title
JP2012512886A5 (enExample)
JP7644139B2 (ja) インダゾール系化合物及び関連使用方法
JP2013507425A5 (enExample)
JP2012525431A5 (enExample)
JP2014506599A5 (enExample)
ES2704704T3 (es) Nuevos derivados de azaindol como inhibidores selectivos de la histona desacetilasa (HDAC) y composiciones farmacéuticas que los comprenden
JP2005508960A5 (enExample)
JP2008530099A5 (enExample)
JP2007521287A5 (enExample)
CN114650868A (zh) Helios的小分子降解剂及其使用方法
JP2019530732A (ja) 免疫モジュレータとして有用な対称または半対称化合物
JP2007516983A5 (enExample)
JP2009528989A5 (enExample)
JP2019534260A5 (enExample)
JP2006524222A5 (enExample)
JP2019536785A5 (enExample)
RU2666730C2 (ru) Диазольные лактамы
JP2017526675A (ja) ヒストンデメチラーゼを阻害するための化合物および方法
JP2005508967A5 (enExample)
JP2004517860A5 (enExample)
JP2012511588A5 (enExample)
CA2425440A1 (en) Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
WO2021194878A1 (en) Selective modulators of mutant lrrk2 proteolysis and associated methods of use
JP2007531744A5 (enExample)
JP2007536231A5 (enExample)